不同肥胖程度非瓣膜性房颤患者直接口服抗凝药血浆浓度观察
单中心观察性研究纳入160例肥胖合并房颤患者,评估直接口服抗凝药峰谷血浆浓度。18.1%和14.4%的患者谷浓度和峰浓度低于范围,达比加群及BMI≥II级肥胖与谷浓度低于范围相关,达比加群与峰浓度低于范围正相关,阿哌沙班负相关。
要点
- 肥胖房颤患者中约18.1%谷浓度和14.4%峰浓度低于范围。
- 达比加群和BMI≥II级肥胖与谷浓度低于范围独立相关。
- 达比加群与峰浓度低于范围正相关,阿哌沙班负相关。
核心结论
- 相当比例肥胖合并房颤患者的直接口服抗凝药血浆浓度低于范围。
- 对BMI≥II级肥胖患者评估直接口服抗凝药血浆浓度可能有用。
研究设计与样本
- 单中心观察性研究,纳入2022年4月至2024年4月肥胖(BMI≥30.0 kg/m2)合并房颤患者160例。
- 评估直接口服抗凝药服药后2小时峰浓度和谷浓度,现场核实服药。
- 采用多因素logistic回归分析评估谷浓度和峰浓度低于范围的相关因素。
主要发现
- 160例患者中女性占33.8%,平均年龄73.2±9.1岁,中位BMI为32.3 kg/m2。
- 处方直接口服抗凝药:阿哌沙班46.8%、利伐沙班21.8%、达比加群16.4%、艾多沙班15.0%。
- 18.1%患者谷浓度低于范围,14.4%患者峰浓度低于范围。
- 谷浓度低于范围者更多使用艾多沙班和达比加群,BMI更高。
- 多因素分析:达比加群(HR 3.039,95%CI 1.155-7.999,p=0.024)和BMI≥II级(OR 2.625,95%CI 1.087-6.335,p=0.032)与谷浓度低于范围相关;达比加群(OR 4.296,95%CI 1.523-12.120,p=0.006)与峰浓度低于范围正相关,阿哌沙班(OR 0.277,95%CI 0.096-0.802,p=0.018)负相关。
临床怎么用
- 对BMI≥II级肥胖合并房颤患者,可考虑评估直接口服抗凝药血浆浓度以识别浓度低于范围者。
- 使用达比加群或艾多沙班的肥胖患者可能更需关注谷浓度低于范围的风险。
局限性
- 单中心观察性研究,样本量有限,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation (AF) has multiple cardio-metabolic comorbidities, including obesity. The use of direct oral anticoagulants (DOACs) in patients with AF and obesity is still uncertain owing to the concern of possible ineffective DOAC plasma concentration. We evaluated the peak and trough plasma concentrations of DOACs in AF patients with different degrees of obesity. METHODS: Observational single-center study including patients with obesity and AF, between April 2022 and April 2024. Obesity was defined as body mass index (BMI) ≥ 30.0 kg/m2. The 2-hour peak and trough DOAC plasma concentrations were assessed. Intake of DOAC was verified on site. Multivariable logistic regression analysis was used to assess the odds ratio (OR) and 95% confidence interval (95% CI) of factors associated with below-range trough concentration (BRTC) and below-range peak concentration (BRPC). RESULTS: In total, 160 patients (33.8% women) with a mean age of 73.2 ± 9.1 years were included. The median BMI was 32.3 kg/m2. DOACs prescribed were apixaban (46.8%), rivaroxaban (21.8%), dabigatran (16.4%), and edoxaban (15.0%); 18.1% and 14.4% had BRTC and BRPC concentrations, respectively. Patients with BRTC were more frequently treated with edoxaban and dabigatran and had a higher BMI. On multivariable logistic regression analysis, dabigatran [hazard ratio (HR) 3.039, 95% CI 1.155-7.999, p = 0.024) and BMI ≥ II class (OR 2.625, 95% CI 1.087-6.335, p = 0.032] were associated with BRTC. Dabigatran (OR 4.296, 95% CI 1.523-12.120, p = 0.006) and apixaban (OR 0.277, 95% CI 0.096-0.802, p = 0.018) were directly and inversely associated with BRPC, respectively. CONCLUSIONS: A nonnegligible proportion of patients with obesity and AF have below-range plasma concentrations of DOACs. Assessment of DOAC plasma concentration in obesity class ≥ II may be useful in these patients.
引用
- Menichelli D, Pannunzio A, Baldacci E, et al. Plasma Concentrations of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Different Degrees of Obesity. Clin Pharmacokinet. 2025. PMID: 39937335. doi:10.1007/s40262-025-01474-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。